CHUM Research Centre
Laboratory of immuno-oncology, CRCHUM
Department of Medicine, Université de Montréal
514 890-8000, ext. 25489 (office) - ext. 25504 (lab)
The patient who needs immediate assistance should not communicate directly with the researcher. Instead, they should call the doctor’s office or take other appropriate measures, such as going to the nearest emergency service.
Breast cancer, kidney cancer, immune system, immunotherapy, T lymphocytes, tumor antigens, indoleamine 2,3 dioxygenase (IDO).
The interaction between the immune system and breast and kidney cancers: The initial goal of this thematic project identifies new tumour antigens in breast cancer through different approaches. We have already identified two candidate antigens for which we are investigating epitopes that may be presented by MHC classes I and II. In addition, we are studying the diversity of immune cell populations invading tumours as well as intra-tumour immuno-regulation mechanisms.
The mechanisms governing the presentation of tumour antigens by MHC class II.
The consequences of IDO expression in human cancers: this theme defines whether IDO expression is frequent and linked to clinical reality, identifies the produced cells, and determines whether T cells are affected by the presence of IDO. If IDO negatively controls T cells and potentially contributes to immunological tolerance, it will be appropriate to target this enzyme to better regulate this control mechanism.
The FRSQ Breast Cancer Network's tissue bank: banked samples include blood mononuclear cells, plasma, tumour sections (gross cell lysates, total RNA and partly frozen in OCT), and healthy margins when available. More than 280 patients have been recruited. These samples are available to the scientific community.